NKX2-5 regulates vessel remodeling in scleroderma-associated pulmonary arterial hypertension
JCI Insight · 2024
DOI: 10.1172/jci.insight.164191 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2024. Verfasst von Ioannis Papaioannou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicine, Department of Inflammation, University College London, Royal Free Campus, London, United Kingdom. Hauptthemen laut MEDLINE: Homeobox Protein Nkx-2.5, Muscle, Smooth, Vascular, Vascular Remodeling. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Arthritis Research UK.
Abstract (Originalsprache)
NKX2-5 is a member of the homeobox-containing transcription factors critical in regulating tissue differentiation in development. Here, we report a role for NKX2-5 in vascular smooth muscle cell phenotypic modulation in vitro and in vascular remodeling in vivo. NKX2-5 is upregulated in scleroderma patients with pulmonary arterial hypertension. Suppression of NKX2-5 expression in smooth muscle cells halted vascular smooth muscle proliferation and migration, enhanced contractility, and blocked the expression of extracellular matrix genes. Conversely, overexpression of NKX2-5 suppressed the expression of contractile genes (ACTA2, TAGLN, CNN1) and enhanced the expression of matrix genes (COL1) in vascular smooth muscle cells. In vivo, conditional deletion of NKX2-5 attenuated blood vessel remodeling and halted the progression to hypertension in a mouse chronic hypoxia model. This study revealed that signals related to injury such as serum and low confluence, which induce NKX2-5 expression in cultured cells, is potentiated by TGF-β and further enhanced by hypoxia. The effect of TGF-β was sensitive to ERK5 and PI3K inhibition. Our data suggest a pivotal role for NKX2-5 in the phenotypic modulation of smooth muscle cells during pathological vascular remodeling and provide proof of concept for therapeutic targeting of NKX2-5 in vasculopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medicine, Department of Inflammation, University College London, Royal Free Campus, London, United Kingdom.
- William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
Förderung
- British Heart Foundation
- Arthritis Research UK
Zitieren
APA
Papaioannou, I., Dritsoula, A., Kang, P., Baliga, R. S., Trinder, S. L., Cook, E., Shiwen, X., Hobbs, A. J., Denton, C. P., Abraham, D. J., & Ponticos, M. (2024). NKX2-5 regulates vessel remodeling in scleroderma-associated pulmonary arterial hypertension. JCI Insight. https://doi.org/10.1172/jci.insight.164191
Vancouver
Papaioannou I, Dritsoula A, Kang P, Baliga RS, Trinder SL, Cook E, et al. NKX2-5 regulates vessel remodeling in scleroderma-associated pulmonary arterial hypertension. JCI Insight. 2024. doi:10.1172/jci.insight.164191
BibTeX
@article{Papaioannou2024,
author = {Papaioannou, Ioannis and Dritsoula, Athina and Kang, Ping and Baliga, Reshma S and Trinder, Sarah L and Cook, Emma and Shiwen, Xu and Hobbs, Adrian J and Denton, Christopher P and Abraham, David J and Ponticos, Markella},
title = {NKX2-5 regulates vessel remodeling in scleroderma-associated pulmonary arterial hypertension},
journal = {JCI Insight},
year = {2024},
doi = {10.1172/jci.insight.164191}
}
EUVIMED